Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Recruiting

Phase 3

Tivozanib & PembrolizumabTesting the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT06661720

Conditions

Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma (RCC)

Stage II Renal Pelvis Cancer AJCC v8

Stage III Renal Pelvis Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Tivozanib

Biospecimen Collection

MRI

Computed Tomography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2025-04-02.